PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches
暂无分享,去创建一个
[1] A. Gjedde,et al. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. , 1995, Biochemical pharmacology.
[2] D J Brooks,et al. Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[3] A. D. Roberts,et al. Localization of trapping of 6‐[18F]fluoro‐L‐m‐tyrosine, an aromatic L‐amino acid decarboxylase tracer for PET , 1999, Synapse.
[4] Vesna Sossi,et al. Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] M. Bergström,et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β-11C) DOPA and PET , 1999, Biological Psychiatry.
[6] Paul Cumming,et al. Dopamine in amygdala gates limbic processing of aversive stimuli in humans , 2008, Nature Neuroscience.
[7] V Kaasinen,et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. , 2001, Brain : a journal of neurology.
[8] Alan C. Evans,et al. Dopa decarboxylase activity of the living human brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[9] Sylvain Houle,et al. Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6‐[18F]‐L‐m‐tyrosine , 2004, Synapse.
[10] Alan C. Evans,et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[11] Juha O. Rinne,et al. Personality traits and brain dopaminergic function in Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Gjedde,et al. Regulation of DOPA Decarboxylase Activity in Brain of Living Rat , 1995, Journal of neurochemistry.
[13] Paul Cumming,et al. Elevated [18F]Fluorodopamine Turnover in Brain of Patients with Schizophrenia: An [18F]Fluorodopa/Positron Emission Tomography Study , 2007, The Journal of Neuroscience.
[14] Doris J. Doudet,et al. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study , 2006, NeuroImage.
[15] A. Gjedde,et al. 6-[18F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[16] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[17] D J Brooks,et al. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. , 1995, The Journal of neuropsychiatry and clinical neurosciences.
[18] Albert Gjedde,et al. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examination , 1982, Brain Research Reviews.
[19] Albert Gjedde,et al. Dopamine Storage Capacity in Caudate and Putamen of Patients with Early Parkinson's Disease: Correlation with Asymmetry of Motor Symptoms , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] B. Långström,et al. Brain kinetics of L-[Β-11 C]DOPA in humans studied by positron emission tomography , 2005, Journal of Neural Transmission / General Section JNT.
[21] Kazuhiko Yanai,et al. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] P. Cumming,et al. Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. , 1986, Life sciences.
[23] A. Lawrence,et al. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. , 2004, Archives of general psychiatry.
[24] E. Hoffman,et al. TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.
[25] C. Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[26] N. Harada,et al. Nicotine modulates dopamine synthesis rate as determined by L‐[β‐11C]DOPA: PET studies compared with [11C]raclopride binding in the conscious monkey brain , 2005, Synapse.
[27] D. Doudet,et al. Loss of metabolites from monkey striatum during PET with FDOPA , 2001, Synapse.
[28] J. Eberling,et al. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. , 2003, Frontiers in bioscience : a journal and virtual library.
[29] A. Gjedde,et al. Cerebral 6‐[18F]fluoro‐L‐DOPA (FDOPA) metabolism in pig studied by positron emission tomography , 1999 .
[30] M E Phelps,et al. Biological imaging and the molecular basis of dopaminergic diseases. , 1997, Biochemical pharmacology.
[31] E. Hoffman,et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.
[32] Paul Cumming,et al. Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study , 2007, Neurobiology of Aging.
[33] Karl J. Friston,et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.
[34] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[35] J. Hietala,et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. , 2000, The American journal of psychiatry.
[36] Juha O. Rinne,et al. Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease , 2005, Neurobiology of Aging.
[37] P. Pollak,et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease , 1999, Journal of the Neurological Sciences.
[38] T. McGlashan,et al. Striatal Dopamine Synthesis in First-degree Relatives of Patients with Schizophrenia , 2008, Biological Psychiatry.
[39] J. Hietala,et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects , 2002, Biological Psychiatry.
[40] J. Haycock,et al. Striatal 3,4‐dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies? , 1995, Annals of neurology.
[41] V. Sossi,et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. , 2002, The American journal of psychiatry.
[42] C Nahmias,et al. Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.
[43] Merja Haaparanta,et al. Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study , 2001, Movement disorders : official journal of the Movement Disorder Society.
[44] M. Grégoire,et al. Anatomic and Biochemical Correlates of the Dopamine Transporter Ligand 11C-PE2I in Normal and Parkinsonian Primates: Comparison with 6-[18F]Fluoro-L-Dopa , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[45] Paul Cumming,et al. Net influx of plasma 6‐[18F]fluoro‐l‐DOPA (FDOPA) to the ventral striatum correlates with prefrontal processing of affective stimuli , 2006, The European journal of neuroscience.
[46] Jarmo Hietala,et al. Personality traits and striatal dopamine synthesis capacity in healthy subjects. , 2003, The American journal of psychiatry.
[47] P. Hartvig,et al. A Comparison of 11C-Labeled l-DOPA and l-Fluorodopa as Positron Emission Tomography Tracers for the Presynaptic Dopaminergic System , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[48] C. Nahmias,et al. Dopamine visualized in the basal ganglia of living man , 1983, Nature.
[49] Albert Gjedde,et al. The kinetic behaviour of [3H]DOPA in living rat brain investigated by compartmental modelling of static autoradiograms , 1997, Journal of Neuroscience Methods.
[50] E. W. EMERY,et al. Compartmental Analysis , 1970, Nature.
[51] H. Kimura,et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.
[52] P. Stoeter,et al. ‘Prefrontal’ cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [18F]‐fluoro‐L‐DOPA‐PET investigation , 2007, Human brain mapping.
[53] J. Langston,et al. Nigrostriatal Reduction of Aromatic L‐Amino Acid Decarboxylase Activity in MPTP‐Treated Squirrel Monkeys: In Vivo and In Vitro Investigations , 2000, Journal of neurochemistry.
[54] J. Langston,et al. Novel observations with FDOPA‐PET imaging after early nigrostriatal damage , 2001, Movement disorders : official journal of the Movement Disorder Society.
[55] J. Hietala,et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia , 1999, Schizophrenia Research.
[56] Albert Gjedde,et al. Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo , 2003, Neuropsychopharmacology.
[57] William J. Jagust,et al. An In Vivo Microdialysis Study of Striatal 6-[18F]Fluoro-L-m-Tyrosine Metabolism , 2004, Neurochemical Research.
[58] A. Gjedde,et al. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6‐[18F]fluoro‐L‐dopa studied with PET in normal control and Parkinson's disease subjects , 2000, Synapse.
[59] J E Holden,et al. Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: implications for PET dopamine studies. , 1997, Life sciences.
[60] Scott T. Grafton,et al. Kinetics and Modeling of l-6-[18F]Fluoro-DOPA in Human Positron Emission Tomographic Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[61] Valtteri Kaasinen,et al. Personality traits and striatal 6-[18F]fluoro-l-dopa uptake in healthy elderly subjects , 2002, Neuroscience Letters.
[62] M. D’Esposito,et al. Working Memory Capacity Predicts Dopamine Synthesis Capacity in the Human Striatum , 2008, The Journal of Neuroscience.
[63] A. Gjedde,et al. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms , 1998, Synapse.
[64] Arne Møller,et al. Quantitative [18F]Fluorodopa/PET and Histology of Fetal Mesencephalic Dopaminergic Grafts to the Striatum of MPTP-Poisoned Minipigs , 2002, Cell transplantation.
[65] Paul Cumming,et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. , 2005, The American journal of psychiatry.
[66] S. Aalto,et al. Striatal subregional 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease: A two‐year follow‐up study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[67] Karl Herholz,et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. , 2005, Archives of neurology.
[68] A. Gjedde,et al. Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[69] V Sossi,et al. A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[70] M. Häusser,et al. Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. , 1988, Biochemical pharmacology.
[71] Janneke Koerts,et al. Striatal dopaminergic activity (FDOPA‐PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease , 2007, The European journal of neuroscience.
[72] J O Rinne,et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. , 2000, Archives of neurology.
[73] A. Meyer-Lindenberg,et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.
[74] A. Carlsson,et al. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. , 2003, Scandinavian journal of psychology.
[75] A. Gjedde,et al. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography. , 1999, Synapse.
[76] J E Holden,et al. Evaluation of Dopaminergic Presynaptic Integrity: 6-[18F]Fluoro-L-Dopa Versus 6-[18F]Fluoro-L-m-Tyrosine , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[77] A. Gjedde,et al. On the accuracy of an [18F]FDOPA compartmental model: evidence for vesicular storage of [18F]fluorodopamine in vivo , 1997, Journal of Neuroscience Methods.
[78] Hans-Georg Buchholz,et al. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge , 2006, NeuroImage.
[79] Albert Gjedde,et al. PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[80] Paul Cumming,et al. Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects , 2008, NeuroImage.
[81] A. Gjedde,et al. Effect of catechol‐O‐methyltransferase inhibition on brain uptake of [18F]fluorodopa: Implications for compartmental modelling and clinical usefulness , 1998, Synapse.
[82] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[83] E. Mcgeer,et al. The Metabolism of [18F]6‐Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Hooded Rat , 1987, Journal of neurochemistry.
[84] C. Patlak,et al. Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.
[85] D B Calne,et al. Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.
[86] V Sossi,et al. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.